Offer - Urjas Oil for just ₹ 1 X
Folitrax 15 Mg Tablet, a prescription drug, is manufactured in various forms such as Tablet. It is typically used for the treatment of Non-Hodgkin Lymphoma, Lymphoma. Secondary and off-label uses of Folitrax 15 Mg Tablet have also been mentioned below.
The right dosage of Folitrax 15 Mg Tablet depends on the age, gender, and medical history of the patient. Individual symptoms and route of administration also determines the right dosage. For detailed information on this, read through the dosage section.
The side effects typically associated with Folitrax 15 Mg Tablet include Abdominal Pain. Besides the aforementioned side effects, there are other adverse effects of Folitrax 15 Mg Tablet as well, which are listed below. Usually, these side effects of Folitrax 15 Mg Tablet go away soon, and do not persist beyond the duration of the treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Folitrax 15 Mg Tablet's effect is Severe during pregnancy and Severe for lactating mothers. Further, the section on Folitrax 15 Mg Tablet related warnings talks about Folitrax 15 Mg Tablet's effects on the liver, heart and kidney.
Individuals suffering from medical conditions like Infections, Liver Disease, Anemia must refrain from the use of Folitrax 15 Mg Tablet since this can cause severe adverse effects. The section on Folitrax 15 Mg Tablet contraindications lists all such conditions.
Besides this, Folitrax 15 Mg Tablet may also have severe interaction with some medicines. Refer to the list below for further details.
You should also be aware that Folitrax 15 Mg Tablet is safe while driving, and is addiction.
Folitrax 15 Mg Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Is the use of Folitrax 15 Mg Tablet safe for pregnant women?
Folitrax shows severe side effect on pregnant women. For this reason, pregnant women should only take it after taking medical advice.
Is the use of Folitrax 15 Mg Tablet safe during breastfeeding?
Folitrax should not be taken without taking your doctor's advice, as it may have severe side effects on breastfeeding women.
What is the effect of Folitrax 15 Mg Tablet on the Kidneys?
There may be some adverse effects on kidney after taking Folitrax. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Folitrax 15 Mg Tablet on the Liver?
Folitrax may cause harmful effects on liver. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Folitrax 15 Mg Tablet on the Heart?
Side effects of Folitrax rarely affect the heart.
If you are suffering from any of the following diseases, you should not take Folitrax 15 Mg Tablet unless your doctor advises you to do so -
Is this Folitrax 15 Mg Tablet habit forming or addictive?
Folitrax 15 Mg Tablet is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can operate a vehicle or heavy machinery after taking Folitrax 15 Mg Tablet since it does not cause drowsiness.
Is it safe?
Folitrax 15 Mg Tablet should be used only after doctor's advice.
Is it able to treat mental disorders?
No, Folitrax 15 Mg Tablet cannot treat any kind of mental disorder.
Interaction between Food and Folitrax 15 Mg Tablet
There is no information on the effects of taking Folitrax 15 Mg Tablet with food, because this topic has not been scientifically researched yet.
Interaction between Alcohol and Folitrax 15 Mg Tablet
Chances of side effects of drinking alcohol while taking Folitrax 15 Mg Tablet are low. If you feel any adverse effects, please seek medical advice as soon as possible.
Folitrax contains methotrexate which is a chemotherapy drug that works in cancer by preventing the DNA synthesis of cancerous cells. It inhibits dihydrofolic acid reductase enzyme which is important for the formation of tetrahydrofolate. Tetrahydrofolate is essential for the synthesis of some DNA components of the cancerous cells. Incase of autoimmune and inflammatory diseases such as psoriasis, rheumatoid arthritis, and Crohn's disease Folitrax works by suppressing the body's normal immune response to inflammation. This results in reduced inflammation and provides relief from the symptoms associated with these diseases.
No, Folitrax is not a steroid. It is an antimetabolite (a chemotherapy drug) and disease-modifying antirheumatic drug (DMARDs) which have immunosuppressant properties. It is used in the treatment of various types of cancer and other diseases such as psoriasis, rheumatoid arthritis, and Crohn's disease.
No, Folitrax does not raise blood sugar levels (hyperglycemia). It has not been reported by the patients who are taking it. However, if you are experiencing increased thirst, trouble concentrating, and frequent urination which are symptoms of increased blood sugar levels (hyperglycemia) then do discuss with your doctor.
Take Folitrax as directed by your doctor. Do not take this medicine longer than prescribed to avoid unpleasant side effects.
Folitrax contains methotrexate (a chemotherapy) which is used in the treatment of various types of cancers. Nonetheless, it has been associated with an increased risk for melanoma, non-Hodgkin's lymphoma, and lung cancer.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Methotrexate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 862-863
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 832-834